Armistice Capital LLC Has $19.66 Million Holdings in AngioDynamics, Inc. $ANGO

Key Points

• Armistice Capital LLC increased its stake in AngioDynamics by 140.1%, now holding 2,094,000 shares valued at approximately $19.66 million.
• Analysts have raised their ratings on AngioDynamics, with a consensus target price of $19.00 and multiple firms giving a buy rating.
• AngioDynamics reported a quarterly earnings surprise with an EPS of ($0.03), exceeding the expected ($0.12), alongside a revenue increase of 13.0% year-over-year.

Armistice Capital LLC boosted its holdings in AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 140.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,094,000 shares of the medical instruments supplier's stock after purchasing an additional 1,222,000 shares during the quarter. Armistice Capital LLC owned approximately 5.16% of AngioDynamics worth $19,663,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of ANGO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in AngioDynamics by 4.6% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,968 shares of the medical instruments supplier's stock valued at $201,000 after purchasing an additional 969 shares during the last quarter. Cerity Partners LLC lifted its holdings in AngioDynamics by 22.0% during the 1st quarter. Cerity Partners LLC now owns 12,929 shares of the medical instruments supplier's stock worth $121,000 after buying an additional 2,333 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in AngioDynamics by 6.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 36,936 shares of the medical instruments supplier's stock worth $339,000 after buying an additional 2,397 shares during the last quarter. Public Employees Retirement System of Ohio lifted its holdings in AngioDynamics by 5.8% during the 4th quarter. Public Employees Retirement System of Ohio now owns 70,972 shares of the medical instruments supplier's stock worth $650,000 after buying an additional 3,900 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its holdings in AngioDynamics by 35.4% during the 4th quarter. Wells Fargo & Company MN now owns 23,715 shares of the medical instruments supplier's stock worth $217,000 after buying an additional 6,200 shares during the last quarter. Institutional investors and hedge funds own 89.43% of the company's stock.

AngioDynamics Trading Down 0.5%

NASDAQ ANGO traded down $0.05 on Friday, reaching $10.68. The stock had a trading volume of 100,167 shares, compared to its average volume of 614,013. The business has a 50 day moving average price of $9.26 and a 200 day moving average price of $9.57. AngioDynamics, Inc. has a 1 year low of $5.83 and a 1 year high of $13.50. The company has a market capitalization of $433.93 million, a price-to-earnings ratio of -12.87 and a beta of 0.64.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last posted its quarterly earnings data on Tuesday, July 15th. The medical instruments supplier reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.09. AngioDynamics had a negative return on equity of 3.20% and a negative net margin of 11.62%.The business had revenue of $80.16 million during the quarter, compared to analysts' expectations of $74.26 million. During the same quarter in the previous year, the firm earned ($0.06) EPS. The firm's revenue was up 13.0% compared to the same quarter last year. AngioDynamics has set its FY 2026 guidance at -0.350--0.250 EPS. On average, analysts anticipate that AngioDynamics, Inc. will post -0.37 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on ANGO shares. HC Wainwright restated a "buy" rating and issued a $16.00 target price on shares of AngioDynamics in a research report on Wednesday, July 16th. Wall Street Zen upgraded AngioDynamics from a "hold" rating to a "buy" rating in a report on Saturday, August 16th. Canaccord Genuity Group lifted their target price on AngioDynamics from $15.00 to $17.00 and gave the stock a "buy" rating in a report on Wednesday, July 16th. Finally, Lake Street Capital started coverage on AngioDynamics in a report on Wednesday, July 16th. They issued a "buy" rating and a $24.00 target price on the stock. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat, AngioDynamics has a consensus rating of "Buy" and an average price target of $19.00.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.